Helix BioPharma's total assets for Q4 2025 were C$18.80M, an increase of 1763.43% from the previous quarter. TSE:HBP total liabilities were C$3.22M for the fiscal quarter, a 34.06% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.